MX2014001023A - Derivados de quinazolina. - Google Patents
Derivados de quinazolina.Info
- Publication number
- MX2014001023A MX2014001023A MX2014001023A MX2014001023A MX2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A
- Authority
- MX
- Mexico
- Prior art keywords
- quinazoline derivatives
- quinazoline
- angiogenesis
- derivatives
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de quinazolina que tienen un sustituyente de benzofurano. También se divulga un método para tratar un desorden relacionado con la angiogénesis con uno de estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/118,019 US7829574B2 (en) | 2008-05-09 | 2008-05-09 | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
PCT/US2009/043347 WO2009137797A2 (en) | 2008-05-09 | 2009-05-08 | Quinazoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014001023A true MX2014001023A (es) | 2014-05-22 |
MX340021B MX340021B (es) | 2016-06-22 |
Family
ID=41265455
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010012168A MX2010012168A (es) | 2008-05-09 | 2009-05-08 | Derivados de quinazolina. |
MX2014001023A MX340021B (es) | 2008-05-09 | 2009-05-08 | Derivados de quinazolina. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010012168A MX2010012168A (es) | 2008-05-09 | 2009-05-08 | Derivados de quinazolina. |
Country Status (21)
Country | Link |
---|---|
US (3) | US7829574B2 (es) |
EP (1) | EP2297115B1 (es) |
JP (2) | JP5856842B2 (es) |
KR (2) | KR101686679B1 (es) |
AU (1) | AU2009244130B2 (es) |
BR (1) | BRPI0908675B1 (es) |
CA (1) | CA2723148C (es) |
CY (1) | CY1117222T1 (es) |
DK (1) | DK2297115T3 (es) |
ES (1) | ES2550245T3 (es) |
HR (1) | HRP20150954T1 (es) |
HU (1) | HUE025723T2 (es) |
MX (2) | MX2010012168A (es) |
MY (1) | MY155566A (es) |
NZ (1) | NZ588900A (es) |
PL (1) | PL2297115T3 (es) |
PT (1) | PT2297115E (es) |
RU (1) | RU2506261C2 (es) |
SI (1) | SI2297115T1 (es) |
TW (1) | TWI458724B (es) |
WO (1) | WO2009137797A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
ES2527940T3 (es) * | 2009-02-11 | 2015-02-02 | Merck Patent Gmbh | Nuevas carboxamidas amino-azaheterocíclicas |
EP2473487B1 (en) | 2009-09-03 | 2016-10-26 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
CN105461702A (zh) | 2014-09-10 | 2016-04-06 | 和记黄埔医药(上海)有限公司 | 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型 |
CA3000988A1 (en) | 2015-10-05 | 2017-04-13 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
WO2017189483A1 (en) * | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
WO2019014044A1 (en) | 2017-07-12 | 2019-01-17 | The Johns Hopkins University | ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES |
CN116987070A (zh) * | 2018-03-30 | 2023-11-03 | 杭州领业医药科技有限公司 | 呋喹替尼的共晶、其制备方法、组合物和用途 |
CN111184698A (zh) * | 2018-11-15 | 2020-05-22 | 和记黄埔医药(上海)有限公司 | 呋喹替尼制剂及其应用 |
CN110898065A (zh) * | 2019-11-25 | 2020-03-24 | 南通大学 | 呋喹替尼或其盐在制备治疗脉络膜新生血管药物中的用途 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
ATE482946T1 (de) * | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür |
US6943161B2 (en) | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
DE10009267A1 (de) * | 2000-02-26 | 2001-08-30 | Goedecke Ag | Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin |
AR035851A1 (es) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
EP1326860A1 (en) * | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Quinazoline derivatives |
WO2002030924A1 (en) * | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
WO2002070477A1 (fr) | 2001-03-01 | 2002-09-12 | Ono Pharmaceutical Co., Ltd. | Acide 2-methylindole-4-acetique, son procede de production et procede pour produire un produit intermediaire de celui-ci |
WO2003048159A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
WO2005005395A2 (en) * | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
CA2551508C (en) * | 2003-12-23 | 2011-08-09 | Pfizer Inc. | Novel quinoline derivatives |
WO2005097137A2 (en) * | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Advanced quinazoline based protein kinase inhibitors |
US20080268460A1 (en) * | 2004-05-20 | 2008-10-30 | Wyeth | Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases |
US20070299092A1 (en) | 2004-05-20 | 2007-12-27 | Wyeth | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors |
KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
WO2006071079A1 (en) | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
WO2007066181A2 (en) | 2005-12-05 | 2007-06-14 | Pfizer Products Inc. | Methods of preparing a vegf-r inhibitor |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
WO2007133773A2 (en) | 2006-05-15 | 2007-11-22 | Senex Biotechnology, Inc | Identification of cdki pathway inhibitors |
TW200922590A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
-
2008
- 2008-05-09 US US12/118,019 patent/US7829574B2/en active Active
- 2008-07-04 TW TW097125278A patent/TWI458724B/zh active
-
2009
- 2009-05-08 AU AU2009244130A patent/AU2009244130B2/en active Active
- 2009-05-08 MX MX2010012168A patent/MX2010012168A/es active IP Right Grant
- 2009-05-08 PL PL09743783T patent/PL2297115T3/pl unknown
- 2009-05-08 NZ NZ588900A patent/NZ588900A/xx unknown
- 2009-05-08 HU HUE09743783A patent/HUE025723T2/en unknown
- 2009-05-08 KR KR1020107024889A patent/KR101686679B1/ko active IP Right Grant
- 2009-05-08 ES ES09743783.4T patent/ES2550245T3/es active Active
- 2009-05-08 MY MYPI2010005148A patent/MY155566A/en unknown
- 2009-05-08 EP EP09743783.4A patent/EP2297115B1/en active Active
- 2009-05-08 MX MX2014001023A patent/MX340021B/es active IP Right Grant
- 2009-05-08 JP JP2011508714A patent/JP5856842B2/ja active Active
- 2009-05-08 SI SI200931257T patent/SI2297115T1/sl unknown
- 2009-05-08 RU RU2010150345/04A patent/RU2506261C2/ru active
- 2009-05-08 DK DK09743783.4T patent/DK2297115T3/en active
- 2009-05-08 PT PT97437834T patent/PT2297115E/pt unknown
- 2009-05-08 BR BRPI0908675-7A patent/BRPI0908675B1/pt active IP Right Grant
- 2009-05-08 CA CA2723148A patent/CA2723148C/en active Active
- 2009-05-08 WO PCT/US2009/043347 patent/WO2009137797A2/en active Application Filing
- 2009-05-08 KR KR1020167009777A patent/KR20160045925A/ko not_active Application Discontinuation
-
2010
- 2010-09-29 US US12/893,872 patent/US8212033B2/en active Active
-
2012
- 2012-06-04 US US13/487,434 patent/US8497372B2/en active Active
-
2014
- 2014-07-04 JP JP2014138608A patent/JP2014177499A/ja active Pending
-
2015
- 2015-08-06 CY CY20151100689T patent/CY1117222T1/el unknown
- 2015-09-09 HR HRP20150954TT patent/HRP20150954T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014001023A (es) | Derivados de quinazolina. | |
MY150493A (en) | Quinazoline derivatives | |
ATE533485T1 (de) | Cetp-inhibitoren | |
UA115026C2 (uk) | Похідні гетероарилпіперидину та -піперазину як фунгіциди | |
TW200745138A (en) | Process for stabilising thiophene derivatives | |
MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
MX2009009290A (es) | Compuestos activos en ppar. | |
TW200621230A (en) | Anti-tumor compounds | |
MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
MX2009011199A (es) | Derivados de pirimidina. | |
EA201170154A1 (ru) | Производные пиридинопиридинонов, способ их получения и применение в терапии | |
TW200745028A (en) | Novel sulphonylpyrroles | |
RS52255B (en) | NALMEFEN HYDROCHLORIDE DIHYDRATE | |
TW200745027A (en) | Novel sulphonylpyrroles | |
HK1145682A1 (en) | Indolinone derivatives and process for their manufacture | |
TW200732281A (en) | Heterocyclic CETP inhibitors | |
TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
NZ579928A (en) | Fluorinated derivatives of deferiprone | |
MX2012008141A (es) | Compuestos y metodos. | |
MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
PH12015501038A1 (en) | Inhibitors of iap | |
SG196785A1 (en) | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4, 3-c] isoquinoline derivatives | |
MX2012005155A (es) | Compuestos de quinazolina. | |
MX2015010611A (es) | Nuevos derivados de dihidroquinolin-2-ona como inhibidores de la aldosterona-sintasa (citocromo p450, familia 11, subfamilia b, polipeptido 2 (cyp11b2) o citocromo p450, familia 11, subfamilia b, polipeptido 1 (cyp11b1)). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |